Kusumoto S, Tachibana T. Central nervous system management remains an evidence gap in first-line tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm. Comment on: “First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level”. haematol [Internet]. 2020Sep.10 [cited 2026Sep.15];. Available from: https://haematologica.org/article/view/14420